BACKGROUND: Soft-tissue sarcomas (STSs) are rare tumors with varied histological presentations. Management and treatment are thus complex, but crucial for patient outcomes. We assess adherence to adult STS management guidelines across two French regions (10% of the French population). We also report standardized incidence. PATIENTS AND METHODS: STS patients diagnosed from 1 November 2006 to 31 December 2007 were identified from pathology reports, medical hospital records, and cancer registries. Guideline adherence was assessed by 23 criteria (validated by Delphi consensus method), and age and sex-standardized incidence rates estimated. Associations between patient, treatment, and institutional factors and adherence with three major composite criteria relating to diagnostic imaging and biopsy as well as multidisciplinary team (MDT) case-review are reported. RESULTS: Two hundred and seventy-four patients were included (57.7% male, mean age 60.8 years). Practices were relatively compliant overall, with over 70% adherence for 10 criteria. Three criteria with perfect Delphi consensus had low adherence: receiving histological diagnosis before surgery, adequacy of histological diagnosis (adherence around 50% for both), and MDT discussion before surgery (adherence <30%). Treatment outside of specialized centers was associated with lower adherence for all three composite criteria, and specific tumor sites and/or features were associated with lower adherence for diagnostic imaging, methods, and MDT meetings. STS standardized incidence rates were 4.09 (European population) and 3.33 (World) /100 000 inhabitants. CONCLUSIONS: Initial STS diagnosis and treatment across all stages (imaging, biopsy, and MDT meetings) need improving, particularly outside specialized centers. Educational interventions to increase surgeon's sarcoma awareness and knowledge and to raise patients' awareness of the importance of seeking expert care are necessary.
BACKGROUND: Soft-tissue sarcomas (STSs) are rare tumors with varied histological presentations. Management and treatment are thus complex, but crucial for patient outcomes. We assess adherence to adult STS management guidelines across two French regions (10% of the French population). We also report standardized incidence. PATIENTS AND METHODS: STS patients diagnosed from 1 November 2006 to 31 December 2007 were identified from pathology reports, medical hospital records, and cancer registries. Guideline adherence was assessed by 23 criteria (validated by Delphi consensus method), and age and sex-standardized incidence rates estimated. Associations between patient, treatment, and institutional factors and adherence with three major composite criteria relating to diagnostic imaging and biopsy as well as multidisciplinary team (MDT) case-review are reported. RESULTS: Two hundred and seventy-four patients were included (57.7% male, mean age 60.8 years). Practices were relatively compliant overall, with over 70% adherence for 10 criteria. Three criteria with perfect Delphi consensus had low adherence: receiving histological diagnosis before surgery, adequacy of histological diagnosis (adherence around 50% for both), and MDT discussion before surgery (adherence <30%). Treatment outside of specialized centers was associated with lower adherence for all three composite criteria, and specific tumor sites and/or features were associated with lower adherence for diagnostic imaging, methods, and MDT meetings. STS standardized incidence rates were 4.09 (European population) and 3.33 (World) /100 000 inhabitants. CONCLUSIONS: Initial STS diagnosis and treatment across all stages (imaging, biopsy, and MDT meetings) need improving, particularly outside specialized centers. Educational interventions to increase surgeon's sarcoma awareness and knowledge and to raise patients' awareness of the importance of seeking expert care are necessary.
Authors: A M Davis; R A Kandel; J S Wunder; R Unger; J Meer; B O'Sullivan; C N Catton; R S Bell Journal: J Surg Oncol Date: 1997-10 Impact factor: 3.454
Authors: I Ray-Coquard; P Thiesse; D Ranchère-Vince; F Chauvin; J-Y Bobin; M-P Sunyach; J-P Carret; B Mongodin; P Marec-Bérard; T Philip; J-Y Blay Journal: Ann Oncol Date: 2004-02 Impact factor: 32.976
Authors: I Ray-Coquard; M C Montesco; J M Coindre; A P Dei Tos; A Lurkin; D Ranchère-Vince; A Vecchiato; A V Decouvelaere; S Mathoulin-Pélissier; S Albert; P Cousin; D Cellier; L Toffolatti; C R Rossi; J Y Blay Journal: Ann Oncol Date: 2012-02-13 Impact factor: 32.976
Authors: M L E A Jansen-Landheer; P Krijnen; M J Oostindiër; W M Kloosterman-Boele; E M Noordijk; M A Nooij; W H Steup; A H M Taminiau; R Vree; P C W Hogendoorn; R A E M Tollenaar; H Gelderblom Journal: Eur J Surg Oncol Date: 2009-06-13 Impact factor: 4.424
Authors: Javier Martin-Broto; Nadia Hindi; Josefina Cruz; Javier Martinez-Trufero; Claudia Valverde; Luis M De Sande; Angeles Sala; Lorena Bellido; Ana De Juan; Jordi Rubió-Casadevall; Roberto Diaz-Beveridge; Ricardo Cubedo; Oscar Tendero; Diego Salinas; Isidro Gracia; Rafael Ramos; Silvia Baguè; Antonio Gutierrez; José Duran-Moreno; Antonio Lopez-Pousa Journal: Oncologist Date: 2018-11-08
Authors: Harald J Hoekstra; Rick L M Haas; Cornelis Verhoef; Albert J H Suurmeijer; Carla S P van Rijswijk; Ben G H Bongers; Winette T van der Graaf; Vincent K Y Ho Journal: Ann Surg Oncol Date: 2017-07-26 Impact factor: 5.344
Authors: Javier Martin-Broto; Nadia Hindi; Samuel Aguiar; Ronald Badilla-González; Victor Castro-Oliden; Matias Chacón; Raquel Correa-Generoso; Enrique de Álava; Davide María Donati; Mikael Eriksson; Martin Falla-Jimenez; Gisela German; Maria Leticia Gobo Silva; Francois Gouin; Alessandro Gronchi; Juan Carlos Haro-Varas; Natalia Jiménez-Brenes; Bernd Kasper; Celso Abdon Lopes de Mello; Robert Maki; Paula Martínez-Delgado; Hector Martínez-Said; Jorge Luis Martinez-Tlahuel; Jose Manuel Morales-Pérez; Francisco Cristobal Muñoz-Casares; Suely A Nakagawa; Eduardo Jose Ortiz-Cruz; Emanuela Palmerini; Shreyaskumar Patel; David S Moura; Silvia Stacchiotti; Marie Pierre Sunyach; Claudia M Valverde; Federico Waisberg; Jean-Yves Blay Journal: Oncologist Date: 2020-09-23 Impact factor: 5.837